ASP7266, a novel antibody against human TSLPR, in the treatment of allergic disease

Numazaki, Mako; Hanaoka, Kaori; Imamura, Emiko; Maeda, Masashi; Arai, Kunizo; Saito, Tetsu; Takamura, Fujiko; Suzuki, Hiroshi; Kubo, Satoshi; Furukawa, Shigetada

doi:10.1016/j.jaci.2017.12.042

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another anti-TSLPRα antibody ASP7266 is able to inhibit TSLP signaling in peripheral white blood cells and mDC-mediated differentiation of naive CD4+ T cells into mature T cells in vitro . Intravenous administration to monkeys effectively blocked CCL17 mRNA expression in peripheral blood cells and suppressed skin allergic reactions in sensitized cynomolgus monkeys ( 160 ). However, phase I clinical trial in asthma patients in Japan has been discontinued for undisclosed reasons ( 161 ).…”

Section: Modulators Of Tslp Signalingmentioning

confidence: 99%

Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer

Marković

Savvides

2020

Front. Immunol.

View full text Add to dashboard Cite

Thymic Stromal Lymphopoietin (TSLP) and Interleukin-7 (IL-7) are widely studied cytokines within distinct branches of immunology. On one hand, TSLP is crucially important for mediating type 2 immunity at barrier surfaces and has been linked to widespread allergic and inflammatory diseases of the airways, skin, and gut. On the other hand, IL-7 operates at the foundations of T-cell and innate lymphoid cell (ILC) development and homeostasis and has been associated with cancer. Yet, TSLP and IL-7 are united by key commonalities in their structure and the structural basis of the receptor assemblies they mediate to initiate cellular signaling, in particular their cross-utilization of IL-7Rα. As therapeutic targeting of TSLP and IL-7 via diverse approaches is reaching advanced stages and in light of the plethora of mechanistic and structural data on receptor signaling mediated by the two cytokines, the time is ripe to provide integrated views of such knowledge. Here, we first discuss the major pathophysiological roles of TSLP and IL-7 in autoimmune diseases, inflammation and cancer. Subsequently, we curate structural and mechanistic knowledge about receptor assemblies mediated by the two cytokines. Finally, we review therapeutic avenues targeting TSLP and IL-7 signaling. We envision that such integrated view of the mechanism, structure, and modulation of signaling assemblies mediated by TSLP and IL-7 will enhance and fine-tune the development of more effective and selective approaches to further interrogate the role of TSLP and IL-7 in physiology and disease.

show abstract

Section: Modulators Of Tslp Signalingmentioning

confidence: 99%